Cervical Cancer Diagnostics Market size is poised to grow with a notable CAGR between 2023 and 2032 due to the strong presence of favorable government initiatives and the surging awareness regarding early disease diagnosis and treatment.
Increasing disease burden of cervical cancer on the globe has fostered a strong demand for diagnostic tests, including colposcopy and pelvic exams to help physicians get an enlarged view to assess the abnormal tissues. According to the CDC (Centers for Disease Control and Prevention), nearly 13,000 new cases of cervical cancer are diagnosed in the U.S. per year.
The increasing efforts taken up by numerous organizations for devising approaches to help in the mitigation of disrupted cervical management as well as screening techniques during the COVID-19 pandemic also influenced the cervical cancer diagnostics market development. Rising R&D investments is further driving the revenue for cervical cancer diagnosis and drugs. However, the intensifying inflation rate along with the influx of massive supply chain disruptions across the healthcare sector caused by the Russia-Ukraine war are some major factors restricting the industry expansion.
Based on type, the cervical cancer diagnostics industry will gain commendable proceeds from the pap smear segment up to 2032. This can be attributed to the increasing adoption of these tests to detect the presence of various cancerous and precancerous cells on the cervix. Pap tests help in preventing cervical cancer by pointing out cervical cell changes in the body that lead to cancer. It mainly ensures early detection resulting in less treatment and time spent on recovery. Rising frequency of these tests for HIV positive women will further influence the segment growth.
With respect to end-use, the cervical cancer diagnostics market from diagnostic centers segment will account for significant share of the cervical cancer diagnostics industry in the forecasted timeline due to the higher availability of cancer specialists in these facilities.
Diagnostic centers assist women with signs and symptoms of cervical cancer in undergoing several diagnostic tests, such as pap test, and HPV test, among others. The increasing deployment of some of the most advanced techniques to diagnose cervical cancers in these centers will also push the industry development.
Based on age group, the cervical cancer diagnostics market from 30-65 segment is poised to witness considerable revenue gains by 2032, on account of rising prevalence of cervical cancer among women of this age bracket. As per American Cancer Society, the disease is mostly diagnosed in women between the ages of 35 and 44, with the average age of diagnosis being 50 years.
Women in the age group of 30-65 years have three testing options; pap test and HPV test (performed every 5 years), pap test (performed every 3 years), and HPV test (performed every 5 years). Growing awareness about these tests among women of this age-group is likely to elevate the segment share in coming years.
North America cervical cancer diagnostics market is slated to expand exponentially through 2032 due to the presence of favorable government policies. This can be accredited to the formulation of several cancer care schemes the support low-income groups in the region. To illustrate, the NBCCEDP scheme offers cervical cancer diagnostics to help underinsured or uninsured people in low incomes in getting access to timely cervical as well as breast cancer screening, treatment, and diagnosis. The growing threat of cervical cancer is also a major contributor to the regional industry gains.
Few of the major cervical cancer diagnostics market players include Abbott Molecular, OncoHealth Corporation, Quest Diagnostics, CooperSurgical, F. Hoffmann-La Roche Ltd., QIAGEN, Arbor Vita Corporation, Dell Guided Therapeutics, and Hologic.